Y Nancy You1,2, Ester Borras2, Kyle Chang2, Brandee A Price1, Maureen Mork1, George J Chang1,3, Miguel A Rodriguez-Bigas1, Brian K Bednarski1, Funda Meric-Bernstam1,4, Eduardo Vilar2,5. 1. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Genomic profiling of colorectal cancer aims to identify actionable somatic mutations but can also discover incidental germline findings. OBJECTIVE: The purpose of this study was to report the detection of pathogenic germline variants that confer heritable cancer predisposition. DESIGN: This was a retrospective study. SETTINGS: The study was conducted at a tertiary-referral institution. PATIENTS: Between 2012 and 2015, 1000 patients with advanced cancer underwent targeted exome sequencing of a 202-gene panel. The subgroup of 151 patients with advanced colorectal cancer who underwent matched tumor-normal (blood) sequencing formed our study cohort. INTERVENTIONS: Germline variants in 46 genes associated with hereditary cancer predisposition were classified according to a defined algorithm based on in silico predictions of pathogenicity. Patients with presumed pathogenic variants were examined for type of mutation, as well as clinical, pedigree, and clinical genetic testing data. MAIN OUTCOME MEASURES: We measured detection of pathogenic germline variants. RESULTS: A total of 1910 distinct germline variants were observed in 151 patients. After filtering, 15 pathogenic germline variants (9.9%) were found in 15 patients, arising from 9 genes of varying penetrance for colorectal cancer (APC (n = 2; 13%), ATM (n = 1; 6%), BRCA1 (n = 2; 13%), CDH1 (n = 2; 13%), CHEK2 (n = 4; 27%), MSH2 (n = 1; 7%), MSH6 (n = 1; 7%), NF2 (n = 1; 7%), and TP53 (n = 1; 7%)). Patients with pathogenic variants were diagnosed at a younger age than those without (median, 45 vs 52 y; p = 0.03). Of the 15 patients, 7 patients (46.7%) with variants in low/moderate- penetrant genes for colorectal cancer would likely have not been tested based on clinical and pedigree criteria, where 2 harbored clinically actionable variants (CDH1 and NF2, 28.5% of 7). LIMITATIONS: This study was limited by its small sample size and advanced-stage patients. CONCLUSIONS: Tumor-normal sequencing can incidentally discover clinically unsuspected germline variants that confer cancer predisposition in 9.9% of patients with advanced colorectal cancer. Precision medicine should integrate clinical cancer genetics to inform and interpret the actionability of germline variants and to provide follow-up care to mutation carriers. See Video Abstract at http://links.lww.com/DCR/A906.
BACKGROUND: Genomic profiling of colorectal cancer aims to identify actionable somatic mutations but can also discover incidental germline findings. OBJECTIVE: The purpose of this study was to report the detection of pathogenic germline variants that confer heritable cancer predisposition. DESIGN: This was a retrospective study. SETTINGS: The study was conducted at a tertiary-referral institution. PATIENTS: Between 2012 and 2015, 1000 patients with advanced cancer underwent targeted exome sequencing of a 202-gene panel. The subgroup of 151 patients with advanced colorectal cancer who underwent matched tumor-normal (blood) sequencing formed our study cohort. INTERVENTIONS: Germline variants in 46 genes associated with hereditary cancer predisposition were classified according to a defined algorithm based on in silico predictions of pathogenicity. Patients with presumed pathogenic variants were examined for type of mutation, as well as clinical, pedigree, and clinical genetic testing data. MAIN OUTCOME MEASURES: We measured detection of pathogenic germline variants. RESULTS: A total of 1910 distinct germline variants were observed in 151 patients. After filtering, 15 pathogenic germline variants (9.9%) were found in 15 patients, arising from 9 genes of varying penetrance for colorectal cancer (APC (n = 2; 13%), ATM (n = 1; 6%), BRCA1 (n = 2; 13%), CDH1 (n = 2; 13%), CHEK2 (n = 4; 27%), MSH2 (n = 1; 7%), MSH6 (n = 1; 7%), NF2 (n = 1; 7%), and TP53 (n = 1; 7%)). Patients with pathogenic variants were diagnosed at a younger age than those without (median, 45 vs 52 y; p = 0.03). Of the 15 patients, 7 patients (46.7%) with variants in low/moderate- penetrant genes for colorectal cancer would likely have not been tested based on clinical and pedigree criteria, where 2 harbored clinically actionable variants (CDH1 and NF2, 28.5% of 7). LIMITATIONS: This study was limited by its small sample size and advanced-stage patients. CONCLUSIONS:Tumor-normal sequencing can incidentally discover clinically unsuspected germline variants that confer cancer predisposition in 9.9% of patients with advanced colorectal cancer. Precision medicine should integrate clinical cancer genetics to inform and interpret the actionability of germline variants and to provide follow-up care to mutation carriers. See Video Abstract at http://links.lww.com/DCR/A906.
Authors: Siân Jones; Valsamo Anagnostou; Karli Lytle; Sonya Parpart-Li; Monica Nesselbush; David R Riley; Manish Shukla; Bryan Chesnick; Maura Kadan; Eniko Papp; Kevin G Galens; Derek Murphy; Theresa Zhang; Lisa Kann; Mark Sausen; Samuel V Angiuoli; Luis A Diaz; Victor E Velculescu Journal: Sci Transl Med Date: 2015-04-15 Impact factor: 17.956
Authors: Lauren L Brusco; Chetna Wathoo; Kenna R Mills Shaw; Vijaykumar R Holla; Ann M Bailey; Amber M Johnson; Yekaterina B Khotskaya; Beate C Litzenburger; Nora S Sanchez; Jia Zeng; Elmer V Bernstam; Cathy Eng; Bryan K Kee; Rodabe N Amaria; Mark J Routbort; Gordon B Mills; John Mendelsohn; Funda Meric-Bernstam Journal: Cancer Date: 2017-11-22 Impact factor: 6.860
Authors: Kara N Maxwell; Steven N Hart; Joseph Vijai; Kasmintan A Schrader; Thomas P Slavin; Tinu Thomas; Bradley Wubbenhorst; Vignesh Ravichandran; Raymond M Moore; Chunling Hu; Lucia Guidugli; Brandon Wenz; Susan M Domchek; Mark E Robson; Csilla Szabo; Susan L Neuhausen; Jeffrey N Weitzel; Kenneth Offit; Fergus J Couch; Katherine L Nathanson Journal: Am J Hum Genet Date: 2016-05-05 Impact factor: 11.025
Authors: Matthew B Yurgelun; Brian Allen; Rajesh R Kaldate; Karla R Bowles; Thaddeus Judkins; Praveen Kaushik; Benjamin B Roa; Richard J Wenstrup; Anne-Renee Hartman; Sapna Syngal Journal: Gastroenterology Date: 2015-05-14 Impact factor: 22.682
Authors: Rachel Pearlman; Wendy L Frankel; Benjamin Swanson; Weiqiang Zhao; Ahmet Yilmaz; Kristin Miller; Jason Bacher; Christopher Bigley; Lori Nelsen; Paul J Goodfellow; Richard M Goldberg; Electra Paskett; Peter G Shields; Jo L Freudenheim; Peter P Stanich; Ilene Lattimer; Mark Arnold; Sandya Liyanarachchi; Matthew Kalady; Brandie Heald; Carla Greenwood; Ian Paquette; Marla Prues; David J Draper; Carolyn Lindeman; J Philip Kuebler; Kelly Reynolds; Joanna M Brell; Amy A Shaper; Sameer Mahesh; Nicole Buie; Kisa Weeman; Kristin Shine; Mitchell Haut; Joan Edwards; Shyamal Bastola; Karen Wickham; Karamjit S Khanduja; Rosemary Zacks; Colin C Pritchard; Brian H Shirts; Angela Jacobson; Brian Allen; Albert de la Chapelle; Heather Hampel Journal: JAMA Oncol Date: 2017-04-01 Impact factor: 31.777
Authors: Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis Journal: Nature Date: 2015-10-01 Impact factor: 49.962
Authors: Bryony A Thompson; Amanda B Spurdle; John-Paul Plazzer; Marc S Greenblatt; Kiwamu Akagi; Fahd Al-Mulla; Bharati Bapat; Inge Bernstein; Gabriel Capellá; Johan T den Dunnen; Desiree du Sart; Aurelie Fabre; Michael P Farrell; Susan M Farrington; Ian M Frayling; Thierry Frebourg; David E Goldgar; Christopher D Heinen; Elke Holinski-Feder; Maija Kohonen-Corish; Kristina Lagerstedt Robinson; Suet Yi Leung; Alexandra Martins; Pal Moller; Monika Morak; Minna Nystrom; Paivi Peltomaki; Marta Pineda; Ming Qi; Rajkumar Ramesar; Lene Juel Rasmussen; Brigitte Royer-Pokora; Rodney J Scott; Rolf Sijmons; Sean V Tavtigian; Carli M Tops; Thomas Weber; Juul Wijnen; Michael O Woods; Finlay Macrae; Maurizio Genuardi Journal: Nat Genet Date: 2013-12-22 Impact factor: 38.330
Authors: Julie C Sapp; Flavia M Facio; Diane Cooper; Katie L Lewis; Emily Modlin; Philip van der Wees; Leslie G Biesecker Journal: Genet Med Date: 2021-08-26 Impact factor: 8.864